ESTS数据库:新辅助治疗后的肺叶或全肺切除并发症与死亡率
结果显示新辅助组心肺并发症发生率更高,但肺叶切除与全肺切除的30日死亡率均与未接受新辅助治疗者相似,支气管胸膜瘘与漏气>5天发生率亦无差异。
要点
- 肺叶切除后新辅助组心肺并发症16%高于对照组12%,但30日死亡率相似(1.9% vs 2.0%)。
- 全肺切除后新辅助组心肺并发症21%高于对照组18%,30日死亡率相似(5.2% vs 5.3%)。
- 新辅助治疗未增加支气管胸膜瘘及漏气>5天的发生风险。
核心结论
- 新辅助化疗与肺叶切除或全肺切除后的围手术期风险升高无关,支持对局部晚期可手术肺癌更广泛地使用该方案。
研究设计与样本
- 5143例(9.7%)接受新辅助治疗,包括单纯化疗3993例与化放疗1150例,并进行倾向性评分匹配分析。
主要发现
- 肺叶切除匹配3824对:新辅助组心肺并发症626例(16%)高于对照组446例(12%),P < 0.001;30日死亡71例(1.9%)vs 75例(2.0%),P = 0.73。
- 肺叶切除匹配组支气管胸膜瘘0.5% vs 0.4%(P = 0.87),漏气>5天9.2% vs 9.9%(P = 0.27)。
- 全肺切除匹配1312对:新辅助组心肺并发症275例(21%)高于对照组18%,P = 0.030;30日死亡68例(5.2%)vs 5.3%,P = 0.86。
- 全肺切除匹配组支气管胸膜瘘1.8% vs 1.4%,P = 0.44。
临床怎么用
- 对局部晚期可手术肺癌患者,新辅助化疗后行肺叶或全肺切除时,应重点防范心肺并发症,而30日死亡风险未见明显增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the postoperative complications and 30-day mortality rates associated with neoadjuvant chemotherapy before major anatomic lung resections registered in the European Society of Thoracic Surgeons (ESTS) database. METHODS: Retrospective analysis on 52 982 anatomic lung resections registered in the ESTS database (July 2007-31 December 2017) (6587 pneumonectomies and 46 395 lobectomies); 5143 patients received neoadjuvant treatment (9.7%) (3993 chemotherapy alone and 1150 chemoradiotherapy). To adjust for possible confounders, a propensity case-matched analysis was performed. The postoperative outcomes (morbidity and 30-day mortality) of matched patients with and without induction treatment were compared. RESULTS: 8.2% of all patients undergoing lobectomies and 20% of all patients undergoing pneumonectomies received induction treatment. Lobectomy analysis: propensity score analysis yielded 3824 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the neoadjuvant group (626 patients, 16% vs 446 patients, 12%, P < 0.001), but 30-day mortality rates were similar (71 patients, 1.9% vs 75 patients, 2.0%, P = 0.73). The incidence of bronchopleural fistula and prolonged air leak >5 days were similar between the 2 groups (neoadjuvant: 0.5% vs 0.4%, P = 0.87; 9.2% vs 9.9%, P = 0.27). Pneumonectomy analysis: propensity score analysis yielded 1312 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the treated patients compared to those without neoadjuvant treatment (neoadjuvant 275 cases, 21% vs 18%, P = 0.030). However, the 30-day mortality was similar between the matched groups (neoadjuvant 68 cases, 5.2% vs 5.3%, P = 0.86). Finally, the incidence of bronchopleural fistula was also similar between the 2 groups (neoadjuvant 1.8% vs 1.4%, P = 0.44). CONCLUSIONS: Neoadjuvant chemotherapy is not associated with an increased perioperative risk after either lobectomy or pneumonectomy, warranting a more liberal use of this approach for patients with locally advanced operable lung cancer.
引用
- Brunelli A, Rocco G, Szanto Z, et al. Morbidity and mortality of lobectomy or pneumonectomy after neoadjuvant treatment: an analysis from the ESTS database. Eur J Cardiothorac Surg. 2020. PMID: 31638692. doi:10.1093/ejcts/ezz287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。